| PMC full text: | Clin Cancer Res. Author manuscript; available in PMC 2009 Sep 22. Published in final edited form as: Clin Cancer Res. 2008 Aug 1; 14(15): 4883–4890. doi: 10.1158/1078-0432.CCR-07-4462 |
Table 1
CRC patients show an increasing number of survivin -reactive CD8+ T cells in peripheral blood on completion of radiation, treatment
| Tetramer (% of CD8) | CD8 (% of PBMC) | ||||||
|---|---|---|---|---|---|---|---|
| Before | During | After | Tetramer set | Before | During | After | |
| CRC 7 | 0.04 | 0.09 | 1 | 14.9 | 14.1 | ||
| CRC 19 | 0 | 0.18 | 1 | 3.2 | 5.4 | ||
| CRC 21 | 0.1 | 0.16 | 1 | 15.5 | 1.6 | ||
| CRC 22 | 0.76 | 2 | 1.2 | ||||
| CRC 23 | 1.57 | 1.93 | 2 | 12.8 | 10.9 | ||
| CRC 24 | 1.16 | 0.27 | 0.97 | 2 | 5.78 | 15.5 | 12.1 |
| CRC 27 | 1.67 | 0.75 | 2 | 1.9 | 4.8 | ||
| CRC 28 | 0.42 | 2 | 9.4 | ||||
| CRC 29 | 0.68 | 2.25 | 2 | 18.1 | 24.5 | ||
| CRC 30 | 1.48 | 1.46 | 2 | 7.24 | 10.1 | ||
| CRC 33 | 0.12 | 0.17 | 2 | 28.2 | 20.8 | ||
| CRC 34 | 0.23 | 0.15 | 0.12 | 2 | 8.4 | 7.6 | 5.3 |
| Rectum 5 | 0.02 | 0.18 | 1 | 11.9 | 14.9 | ||
| Rectum 8 | 0.04 | 0.03 | 0.07 | 1 | 14.7 | 11.5 | 10.5 |
| Rectum 10 | 0.01 | 0.07 | 1 | 18.2 | 8.95 | ||
| prostate 05 | 0.1 | 0.11 | 1 | 15.2 | 21.6 | ||
| prostate 1 | 0.23 | 0.29 | 0.37 | 2 | 16.4 | 13.7 | 13.8 |
| prostate 2 | 0.12 | 0.05 | 0.25 | 2 | 17 | 18.7 | 17.7 |
| prostate 3 | 0.28 | 0.23 | 0.53 | 2 | 4 | 4.1 | 3.3 |
| prostate 4 | 1.33 | 0.16 | 2 | 17.7 | 18.5 | ||
| prostate 5 | 0.22 | 0.12 | 2 | 8.9 | 8.1 | ||
| prostate 6 | 0.15 | 0.16 | 0.15 | 2 | 13.9 | 15.7 | 7.3 |
| prostate 9 | 0.46 | 0.16 | 0.15 | 2 | 5.4 | 7.7 | 9 |
| prostate 11 | 0.32 | 0.31 | 0.21 | 2 | 28 | 40 | 36 |
| prostate 12 | 0.15 | 0.5 | 0.32 | 2 | 6 | 2.5 | 5.5 |
| prostate 13 | 0.1 | 0.14 | 2 | 5.4 | 5.5 | ||
NOTE: Data are from 15 HLA-A2 – positive patients with CRC and 11 patients with prostate cancer. CRC indicates patients that were part of a cyclooxygertase-2 inhibitor clinical trial. Data are CD8+ Tcells staining positive with the tetramer for survivin (%) and levels of CD8+ PBMCs (%). Two batches of survivin tetra merwere used and are indicated. Five healthy volunteers served as control. Gray fields highlight those samples that stained above the background level (≥mean ± 2× SD of % survivin-reactive CD8+ T cells in the healthy volunteers for that tetramer batch).